Phaseline

Targets › ITGB2

ITGB2 (Integrin beta-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology.

Integrin ITGAL:ITGB2 is a receptor for ICAM1, ICAM2 and ICAM3. Integrin ITGAL:ITGB2 is also a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Integrins ITGAM:ITGB2 and ITGAX:ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. (UniProt, P05107)

Open in Phaseline: the race on ITGB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lunan Better PharmaceuticalLifitegrast
Integrin alpha-L/beta-2 (LFA-1) antagonist
ITGAL, ITGB2Phase 3Dry Eye Disease (DED)–

Conditions

Dry Eye Disease (DED) (1)

Modalities

–

Companies

Lunan Better Pharmaceutical (1)

Related targets

ITGAL (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.